SPINREACT

At Spinreact we are committed to facilitating access to clinical analysis in the places it is really needed. Every day we strive to offer solutions adapted to the needs of our distributors and the laboratories around the world.

biomakers

BIOMAKERS es Centro de Medicina Genómica de Precisión y Biotecnología especializado en Análisis genómicos, Big Data y desarrollo de Tecnología para Oncología y otras áreas terapéuticas complejas en Latinoamérica y USA . Cuenta con Laboratorios Moleculares propios integrados en Argentina, Mexico y Brasil, en donde se llevan a cabo estudios de biomarcadores asociados al diagnóstico genómico-molecular y una Oficina de Big Data & Technology en San Francisco, USA. BIOMAKERS prioriza la innovación a partir de la incorporación de nuevas tecnologías a través de su departamento de I+D, y el desarrollo de Plataformas Tecnológicas con Inteligencia Artificial, junto con el desarrollo e implementación de nuevos estudios genéticos para 17 países de Latinoamérica, habiendo construido el BIOBANCO de tumores avanzados y el Dataset para cáncer más importante y grande de Latino América. BIOMAKERS está conformada por profesionales con amplia trayectoria en el ámbito científico, médico, de investigación clínica, y de desarrollo de tecnología quienes cuentan con lun expertise único en la región y conforman el grupo más experto de LATAM en Medicina de Precisión. BIOMAKERS se compromete con la comunidad, a través de políticas de responsabilidad social empresaria (RSE). Desde su fundación ha comenzado a trazar esta trayectoria, a través de campañas de difusión y capacitación de diversos entes sociales (proveedores, clientes, comunidad en general), así como también programas específicos de estudios genéticos en la población latinoamericana.

Connect Biopharma

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from our T cell-driven research. Our lead product candidate, CBP-201 — an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) — has been in clinical trials for the treatment of AD, asthma, and CRSwNP. Our second lead product candidate, CBP-307 — a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1) — has been in clinical trials for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD). Furthermore, we have started the clinical development of an additional product candidate, CBP-174 — a peripherally acting antagonist of histamine receptor 3 — for the treatment of pruritus associated with AD. With clinical development activities in the United States, China, Europe, and Australia, and operations in those geographies as well as Hong Kong, Connect Biopharma is building a rich global pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. For additional information about Connect Biopharma, please visit our website at www.connectbiopharm.com

Syapse

To achieve more precise care for every patient, we need to transform real-world evidence into insights that can directly impact care. At Syapse, that is real-world care. It’s found in the way we empower healthcare organizations to work together in active, transparent partnerships, delivering complete patient insights to answer the questions that matter and then purposefully applying it at where patients receive care – driving real impact for cancer patients and beyond.

Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Our goal is to enhance the lives of people living with rare diseases.